Turkish Journal of Nephrology
Original Article

The Efficacy of Cinacalcet in the Treatment of Hyperparathyroidism in Turkish Hemodialysis Patient Population

1.

Department of Nephrology, Kahramanmaraş Sütçü İmam University, Faculty of Medicine, Kahramanmaraş, Turkey

2.

Kocaeli University, Faculty of Medicine, Kocaeli, Turkey

3.

İzmir Tepecik Training and Research Hospital, İzmir, Turkey

4.

Manisa State Hospital, Manisa, Turkey

5.

Selcuk University, Meram Faculty of Medicine, Department of Nephrology, Konya, Turkey

6.

Erzurum Regional Training and Research Hospital, Erzurum, Turkey

7.

Rize Recep Tayyip Erdoğan University, Faculty of Medicine, Rize, Turkey

8.

Aydın State Hospital, Aydın, Turkey

9.

Şanlıurfa Harran University, Faculty of Medicine, Şanlıurfa, Turkey

10.

Antakya Mustafa Kemal University, Faculty of Medicine, Antakya, Turkey

11.

Malatya State Hospital, Malatya, Turkey

12.

Kayseri Erciyes University, Faculty of Medicine, Kayseri, Turkey

13.

Department of Endocrinology, Kahramanmaraş Sütçü İmam University, Faculty of Medicine, Kahramanmaraş, Turkey

14.

Department of Nephrology, Dr. Lütfi Kırdar Kartal Training and Research Hospital, İstanbul, Turkey

15.

Adana Numune Training and Research Hospital, Adana, Turkey

16.

Uludağ University, Faculty of Medicine, Bursa, Turkey

17.

Balıkesir State Hospital, Balıkesir, Turkey

18.

İzzet Baysal State Hospital, Bolu, Turkey

19.

Samsun Training and Research Hospital, Antalya, Turkey

20.

Çorum Hitit University, Faculty of Medicine, Çorum, Turkey

21.

Abant İzzet Baysal University, Faculty of Medicine, Bolu, Turkey

22.

Isparta State Hospital, Isparta, Turkey

23.

Osmaniye State Hospital, Osmaniye, Turkey

24.

Karabük Training and Research Hospital, Karabük, Turkey

25.

İstanbul Training and Research Hospital, İstanbul, Turkey

26.

Şişli Etfal Training and Research Hospital, İstanbul, Turkey

27.

Sakarya Training and Research Hospital, Sakarya, Turkey

28.

Kırşehir State Hospital, Kırşehir, Turkey

29.

Ersin Arslan State Hospital, Gaziantep, Turkey

30.

Gülhane Military Medical Academy, Ankara, Turkey

Turkish J Nephrol 2016; 25: 192-198
DOI: 10.5262/tndt.2016.1002.12
Read: 2246 Downloads: 838 Published: 05 February 2019

OBJECTIVE: Cinacalcet reduces parathyroid hormone levels by increasing the sensitivity of the parathyroid gland to calcium. In this study, we firstly aimed to evaluate the efficacy of cinacalcet in Turkish hemodialysis patients.

MATERIAL and METHODS: 4483 hemodialysis patients were screened and 469 patients who had used cinacalcet were included in the study. The patients were divided into 4 groups according to drug usage durations (Group 1: 3 months, Group 2: 6 months, Group 3: 9 months and Group 4: 12 months). The patients’ Parathormone, Ca, P and CaxP levels at the 3rd, 6th, 9th and 12th months were compared to the start of treatment and previous months.

RESULTS: The levels of Parathormone, Ca, P and CaxP significantly decreased compared to their initial levels in all groups (from 1412 pg/ml to 1222 pg/mL for Parathormone, p<0,001) in the 3rd month. However, this reduction was not continued in the subsequent months (Parathormone: 1381 pg/ ml for the 12th month).

CONCLUSION: Cinacalcet may not provide adequate benefit in control of hyperparathyroidism in Turkish hemodialysis patient population.

Files
EISSN 2667-4440